Combination Therapy of Lapatinib and Capecitabine forErbB2-Positive Metastatic or Locally Advanced BreastCancer: Results from the Lapatinib Expanded AccessProgram (LEAP) in Central and Eastern Europe | Zendy

Richard Greil | Zendy; Simona Borštnar | Zendy; Katarína Petráková | Zendy; Yiola Marcou | Zendy; Joanna Pikiel | Zendy; Marek Z. Wojtukiewicz | Zendy; I Koza | Zendy; Günther Steger | Zendy; Meinolf Linn | Zendy; Ash Das Gupta | Zendy; Karel Cwiertka | Zendy

Open Access

Combination Therapy of Lapatinib and Capecitabine forErbB2-Positive Metastatic or Locally Advanced BreastCancer: Results from the Lapatinib Expanded AccessProgram (LEAP) in Central and Eastern Europe

Author(s) -

Richard Greil,

Simona Borštnar,

Katarína Petráková,

Yiola Marcou,

Joanna Pikiel,

Marek Z. Wojtukiewicz,

I Koza,

Günther Steger,

Meinolf Linn,

Ash Das Gupta,

Karel Cwiertka

Publication year - 2011

Publication title -

onkologie

Language(s) - English

Resource type - Journals

eISSN - 1423-0240

pISSN - 0378-584X

DOI - 10.1159/000327710

Subject(s) - lapatinib , capecitabine , medicine , trastuzumab , ejection fraction , adverse effect , metastatic breast cancer , oncology , breast cancer , cancer , colorectal cancer , heart failure

The Lapatinib Expanded Access Program (LEAP) was initiated in 45 countries to provide lapatinib in combination with capecitabine to patients with ErbB2 (HER2)-positive breast cancer already treated with anthracyclines, taxanes and trastuzumab. We report the results from 12 Central and Eastern European countries.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research